Kimberly Humulock, DO
Internal Medicine · Warwick, RINPI 1831154574
Payments from drug & device makers
Across 116 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$333
- AstraZeneca$271
- AbbVie$211
- Pfizer$200
- Lilly USA, LLC$170
- Novo Nordisk$112
- plus $470 from 17 others
What the payments were for
- Food & beverage$1,58890%
- Education$17810%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 22 | $333 |
| AstraZeneca | 17 | $271 |
| AbbVie(2 entities) | 14 | $211 |
| Pfizer | 18 | $200 |
| Lilly USA, LLC | 11 | $170 |
| Novo Nordisk | 6 | $112 |
| Johnson & Johnson | 4 | $77 |
| Boehringer Ingelheim | 4 | $62 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| GSK | 2 | $34 |
| Novartis | 2 | $33 |
| Amgen | 2 | $31 |
| Exact Sciences | 1 | $29 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Abbott | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Kaleo, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $14 |
| Strongbridge US Inc. | 1 | $11 |
| Biodelivery Sciences International, Inc. | 1 | $11 |
How this compares
$1,766 in reported general payments places this provider in the 85th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 205 | $168,944 |
| JardianceEmpagliflozin | 141 | $118,639 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 120 | $88,843 |
| OzempicSemaglutide | 75 | $86,198 |
| MyrbetriqMirabegron | 63 | $39,993 |
| Breo ElliptaFluticasone/Vilanterol | 79 | $33,687 |
| TrulicityDulaglutide | 28 | $28,878 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 38 | $24,122 |
| FarxigaDapagliflozin Propanediol | 17 | $16,919 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $16,242 |
| EntrestoSacubitril/Valsartan | 28 | $14,266 |
| MounjaroTirzepatide | 12 | $13,339 |
| LinzessLinaclotide | 14 | $11,249 |
| Fluticasone Propionate | 437 | $10,490 |
| Lagevrio (Eua)Molnupiravir | 15 | $7,382 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $200 | $168,944205 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $34 | $146,652237 claims |
| Boehringer IngelheimJardiance | $62 | $118,639141 claims |
| Novo NordiskOzempic | $112 | $86,19875 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $170 | $42,21740 claims |
| Astellas Pharma US IncMyrbetriq | $333 | $39,99363 claims |
| AstraZenecaFarxiga | $271 | $16,91917 claims |
| AbbVieLinzess, Synthroid | $211 | $15,29196 claims |
| NovartisEntresto | $33 | $14,26628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 808 internal medicine providers in Rhode Island.
Other internal medicine in Warwick
- Vikram MalikWarwick$12K
- Munawar AzamWarwick$8K
- David FriedEast Greenwich$37.2M
- Gregory AllenCranston$12.2M
- Kathleen GordonJohnston$1.1M
- William BeliveauJohnson$962K
- Scott WilsonCumberland$907K
- Aaron SamuelsProvidence$751K
- Frank D'alessandroLincoln$541K
- Andrew HsuProvidence$409K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.